Article
Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores.
American journal of hematology - 1 Jun 2023
Bachelot Amélie, Bouvier Anne, Riou Jérémie, Thepot Sylvain, Giltat Aurélien, Nunes Gomes Christopher, Paillassa Jérôme, Jouanneau-Courville Rébecca, Renard Maxime, Beucher Annaelle, Cottin Laurane, Wiber Margaux, Ribourtout Bénédicte, Geneviève Franck, Luque Paz Damien, Tanguy-Schmidt Aline, Ugo Valérie, Hunault-Berger Mathilde, Blanchet Odile, Orvain Corentin
Abstract excerpt
The aim of this study was to evaluate how comorbidities and molecular landscape relate to outcome in patients with acute myeloid leukemia (AML) aged 60 years or older who received intensive induction therapy. In 91 patients, 323 mutations were identified in 77 genes by next-generation sequencing, with a median of four mutations per patient, with NPM1, FLT3, TET2, and DNMT3A being the most frequently mutated...
Topics
Join the communities discussing this publication.